Scientific article
Open access

Traitement hormonal substitutif de l’hypoparathyroïdie : quels bénéfices ?

Other titlePTH-replacement therapy in hypoparathyroidism : what benefits ?
Published inRevue médicale suisse, vol. 17, no. 735, p. 788-792
Publication date2021-04-21

Hypoparathyroidism is a rare disease. In the last decade, important publications have described clinical disease progression and long-term complications. Furthermore, this condition has benefited from major therapeutic advances with the emergence of a hormonal substitution therapy with injectable parathyroid hormone, rhPTH (1-84) (Recombinant human parathyroid hormone, 1-84). Conventional therapy, with calcium supplements and active vitamin D analogue, is effective but does not always fulfill all therapeutic targets and is associated with hypercalciuria. In most patients, therapy with rhPTH (1-84) is associated with a substantial reduction of at least 50% in the need for calcium and active vitamin D along with maintenance of serum calcium. Additionally, rhPTH (1-84) is associated with decreased in 24h urinary calcium excretion with preservation of renal function, which can be a major asset.

  • Calcium
  • Hormone Replacement Therapy
  • Humans
  • Hypoparathyroidism / drug therapy
  • Parathyroid Hormone / therapeutic use
  • Recombinant Proteins
  • Vitamin D / therapeutic use
Citation (ISO format)
TROMBETTI, Andrea, BÉGIN, Marie-Josée. Traitement hormonal substitutif de l’hypoparathyroïdie : quels bénéfices ? In: Revue médicale suisse, 2021, vol. 17, n° 735, p. 788–792. doi: 10.53738/REVMED.2021.17.735.0788
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation09/14/2022 2:22:00 PM
First validation09/14/2022 2:22:00 PM
Update time03/16/2023 10:51:12 AM
Status update03/16/2023 10:51:12 AM
Last indexation01/17/2024 11:10:15 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack